Holen Sie sich die Stockscreener-App
4.22
4.95%
-0.22
Handel nachbörslich:
4.14
-0.08
-1.90%
Schlusskurs vom Vortag:
$4.44
Offen:
$4.4
24-Stunden-Volumen:
33,171
Relative Volume:
0.55
Marktkapitalisierung:
$12.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.77M
KGV:
-0.4261
EPS:
-9.9046
Netto-Cashflow:
$-6.52M
1W Leistung:
-13.17%
1M Leistung:
-27.49%
6M Leistung:
+143.93%
1J Leistung:
-49.57%
1-Tages-Spanne:
$4.12
$4.56
1-Wochen-Bereich:
$3.77
$4.82
52-Wochen-Spanne:
$1.31
$10.75
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Firmenname
Adial Pharmaceuticals Inc
Sektor
Branche
Telefon
434-422-9800
Adresse
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
4.22 | 12.38M | 0 | -7.77M | -6.52M | -9.9046 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-10-30 | Eingeleitet | Maxim Group | Buy |
| 2018-10-11 | Eingeleitet | Dawson James | Buy |
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade
Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan
Adial Shareholders Approve Key Proposals, Meeting Adjourned - TipRanks
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance - TipRanks
Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance - TradingView
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - Kalkine Media
ADIL Should I Buy - Intellectia AI
Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade
Lucid Capital initiates coverage on Adial with Buy rating - scanx.trade
Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Adial (ADIL) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Session Move - vinanet.vn
Adial (ADIL) Shares: Finishes 14.56% Down at $5.31; Current Setup: the Current Price Sits Inside the Supplied Technical Range at the CloseSign of Strength - dars.gov.et
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn
Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 46.85% Positive SurpriseCash Flow Report - Vinanet
Adial Pharmaceuticals Acquires Azora Therapeutics in Stock-and-Preferred Deal - Minichart
Adial Pharmaceuticals announces annual shareholder meeting - Bitget
Form 8K Adial Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals (NASDAQ: ADIL) outlines Azora merger, heavy dilution and $53M share overhang - Stock Titan
Adial Pharmaceuticals Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support LevelSafe Entry Stocks - careplusvn.com
Adial Pharmaceuticals Price Target Announced at $11.00/Share by Alliance Global Partners - Moomoo
Adial Pharmaceuticals Initiated at Buy by Alliance Global Partners - Moomoo
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
A. G. P. Initiates Adial Pharmaceuticals(ADIL.US) With Buy Rating, Announces Target Price $11 - moomoo.com
ADIL Q1 2026 Earnings: EPS Beats Estimates Sharply, But Revenue Remains AbsentEarnings Revision Downgrade - careplusvn.com
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Fuels 4.44% Share UptickFinancial Data - Vinanet
Adial Pharmaceuticals Inc (ADIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adial Pharmaceuticals Inc (ADIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey
Finanzdaten der Adial Pharmaceuticals Inc-Aktie (ADIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):